Diagnostic Challenges in Thrombotic Microangiopathies

Summary of Presentations from the Alexion-Sponsored Symposium, held at the 51st ERA–EDTA Congress, Amsterdam, the Netherlands, on 1st June 2014

Chairperson: Dirk Kuypers1
Speakers: Dirk Kuypers,1 Josep Campistol,2 Christophe Legendre3

1. University of Leuven, Leuven, Belgium
2. University of Barcelona, Barcelona, Spain
3. Necker-Enfants Malades Hospital and Université Paris Descartes, Paris, France

Disclosure: The authors are invited speakers for Alexion and have received honorarium from Alexion, Astellas, Bristol Myers Squibb, Novartis, Pfizer, and Roche.
Acknowledgements: Writing assistance provided by Dr Juliet Bell apothecom scopemedical.
Support: Medical writing assistance was funded by Alexion Pharma International. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Alexion.
Citation: EMJ Neph. 2014;1:28-36.

Meeting Summary

The Alexion Satellite Symposium provided an introduction to thrombotic microangiopathies (TMA) by Prof Dirk Kuypers, who described atypical haemolytic uraemic syndrome (aHUS) as a rare but severe disease that causes TMA and can result in organ failure. Prof Josep Campistol presented two patient cases to illustrate the need to make a differential diagnosis between aHUS, thrombotic thrombocytopaenic purpura (TTP), and Shiga toxin-related-HUS (STEC-HUS). Prof Christophe Legendre then described aHUS clinical management, introduced eculizumab as the only approved treatment for aHUS, and provided an overview of the efficacy and safety data from recent clinical trials.

Download (PDF, 97KB)

Comments are closed.